Boston Scientific Corp (BSX)vsMaxCyte Inc (MXCT)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
MXCT
MaxCyte Inc
$0.69
-6.81%
HEALTHCARE · Cap: $80.74M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 58222% more annual revenue ($20.07B vs $34.42M). BSX leads profitability with a 14.4% profit margin vs -132.6%. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
MXCT
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Intrinsic value data unavailable for MXCT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -23.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a growth stock while MXCT is a turnaround play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.43 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 32/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a leading innovator in cell-engineering solutions, renowned for its proprietary Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins across diverse cell types. Catering to a broad spectrum of clients, including major biopharmaceutical companies and research institutions, MaxCyte plays a critical role in the rapidly evolving cell and gene therapy market. The company's advanced platforms are essential for the development of cutting-edge cell-based therapies and vaccines, positioning MaxCyte to capitalize on significant growth opportunities in the healthcare sector. With a steadfast dedication to advancing transformative treatment options, MaxCyte is well-equipped to address the escalating global demand for innovative therapeutic modalities.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?